Product Description
respiratory syncytial virus (RSV) fusion inhibitor
Mechanisms of Action: FP Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Vaxart
Company Location: Western America
Company Founding Year: 2004
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Respiratory Syncytial Virus Infections
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00504907 |
BTA9881-01 | P1 |
Completed |
Respiratory Syncytial Virus Infections |
2008-12-01 |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|